{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:35:50Z","timestamp":1793745350440,"version":"4.6.1"},"reference-count":50,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Thrombosis and bleeding are significant contributors to morbidity and mortality in patients with hematological cancer, and the impact of altered fibrinolysis on bleeding and thrombosis risk is poorly understood. In this prospective cohort study, we investigated the dynamics of fibrinolysis in patients with hematological cancer. Fibrinolysis was investigated before treatment and 3\u00a0months after treatment initiation. A dynamic clot formation and lysis assay was performed beyond the measurement of plasminogen activator inhibitor 1, tissue- and urokinase-type plasminogen activators (tPA and uPA), plasmin-antiplasmin complexes (PAP), \u03b1-2-antiplasmin activity, and plasminogen activity. Clot initiation, clot propagation, and clot strength were assessed using rotational thromboelastometry. A total of 79 patients were enrolled. Patients with lymphoma displayed impaired fibrinolysis with prolonged 50% clot lysis time compared with healthy controls (P\u00a0= .048). They also displayed decreased clot strength at follow-up compared with at diagnosis (P\u00a0= .001). A patient with amyloid light-chain amyloidosis having overt bleeding\u00a0at diagnosis displayed hyperfibrinolysis, indicated by a reduced 50% clot lysis time, \u03b1-2-antiplasmin activity, and plasminogen activity, and elevated tPA and uPA. A patient with acute promyelocytic leukemia also displayed marked hyperfibrinolysis with very high PAP, indicating extreme plasmin generation, and clot formation was not measurable, probably because of the extremely fast fibrinolysis. Fibrinolysis returned to normal after treatment in both patients. In conclusion, patients with lymphoma showed signs of impaired fibrinolysis and increased clot strength, whereas hyperfibrinolysis was seen in patients with acute promyelocytic leukemia and light-chain amyloidosis. Thus, investigating fibrinolysis in patients with hematological cancer could have diagnostic value.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023011379","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T19:11:33Z","timestamp":1695841893000},"page":"7056-7066","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6289-4869","authenticated-orcid":false,"given":"S\u00f8ren Thorgaard","family":"B\u00f8nl\u00f8kke","sequence":"first","affiliation":[{"name":"1Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark"},{"name":"2Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fenger-Eriksen","sequence":"additional","affiliation":[{"name":"2Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"},{"name":"3Department of Anesthesiology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-8694","authenticated-orcid":false,"given":"Hans Beier","family":"Ommen","sequence":"additional","affiliation":[{"name":"2Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"},{"name":"4Department of Hematology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Mette","family":"Hvas","sequence":"additional","affiliation":[{"name":"5Faculty of Health, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"issue":"1","key":"2023112721412733800_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Prim"},{"issue":"8","key":"2023112721412733800_bib2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/jth.14475","article-title":"Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study","volume":"17","author":"Adelborg","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"2023112721412733800_bib3","author":"Campo","year":"2017"},{"issue":"11","key":"2023112721412733800_bib4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41408-022-00728-z","article-title":"Survival trends in hematological malignancies in the Nordic countries through 50 years","volume":"12","author":"Hemminki","year":"2022","journal-title":"Blood Cancer J"},{"issue":"12","key":"2023112721412733800_bib5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023112721412733800_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"2023112721412733800_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/PPO.0000000000000450","article-title":"Molecular classification and treatment of diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma","volume":"26","author":"Roschewski","year":"2020","journal-title":"Cancer J"},{"issue":"12","key":"2023112721412733800_bib8","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.3390\/diagnostics11122174","article-title":"Advances in lymphoma molecular diagnostics","volume":"11","author":"Kos","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2023112721412733800_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.thromres.2020.12.021","article-title":"Survival patterns among venous thromboembolism patients with hematologic malignancies in Alberta, Canada from 2003 to 2015","volume":"199","author":"Alam","year":"2021","journal-title":"Thromb Res"},{"issue":"10","key":"2023112721412733800_bib10","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"13","key":"2023112721412733800_bib11","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","article-title":"Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera","volume":"96","author":"Falanga","year":"2000","journal-title":"Blood"},{"issue":"suppl 1","key":"2023112721412733800_bib12","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/00001721-199401000-00004","article-title":"The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions","volume":"5","author":"Falanga","year":"1994","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"13","key":"2023112721412733800_bib13","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood-2016-09-739334","article-title":"Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia","volume":"129","author":"Cao","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2023112721412733800_bib14","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/ATVBAHA.119.312463","article-title":"Neutrophil extracellular traps: villains and targets in arterial, venous, and cancer-associated thrombosis","volume":"39","author":"Th\u00e5lin","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"2023112721412733800_bib15","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1111\/j.1538-7836.2011.04465.x","article-title":"Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus","volume":"9","author":"Swystun","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2023112721412733800_bib16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/bloodadvances.2020003149","article-title":"Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer","volume":"5","author":"Hisada","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2023112721412733800_bib17","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood-2004-08-3253","article-title":"Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis","volume":"105","author":"Lisman","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2023112721412733800_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.blre.2006.04.001","article-title":"Haemostatic problems in acute promyelocytic leukaemia","volume":"20","author":"Arbuthnot","year":"2006","journal-title":"Blood Rev"},{"issue":"1","key":"2023112721412733800_bib19","doi-asserted-by":"crossref","first-page":"101353","DOI":"10.1016\/j.beha.2022.101353","article-title":"Thrombosis and bleeding in hematological malignancy","volume":"35","author":"Wang","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"2023112721412733800_bib20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1055\/s-0039-1693478","article-title":"The role of abnormal hemostasis and fibrinolysis in morbidity and mortality of acute promyelocytic leukemia","volume":"45","author":"Kwaan","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"7","key":"2023112721412733800_bib21","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.leukres.2010.11.008","article-title":"The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia","volume":"35","author":"Liu","year":"2011","journal-title":"Leuk Res"},{"issue":"7","key":"2023112721412733800_bib22","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1111\/bph.12978","article-title":"Annexin A2 complexes with S100 proteins: structure, function and pharmacological manipulation","volume":"172","author":"Liu","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"5","key":"2023112721412733800_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-0041-1725099","article-title":"Altered fibrinolysis in hematological malignances","volume":"47","author":"B\u00f8nl\u00f8kke","year":"2021","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"2023112721412733800_bib24","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1055\/s-0037-1615590","article-title":"Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis","volume":"94","author":"van Marion","year":"2005","journal-title":"Thromb Haemost"},{"issue":"6","key":"2023112721412733800_bib25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/eci.12269","article-title":"Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma","volume":"44","author":"Undas","year":"2014","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"2023112721412733800_bib26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.thromres.2014.04.025","article-title":"Platelet-related fibrinolysis resistance in patients suffering from PV. Impact of clot retraction and isovolemic erythrocytapheresis","volume":"134","author":"Rusak","year":"2014","journal-title":"Thromb Res"},{"key":"2023112721412733800_bib27","doi-asserted-by":"crossref","first-page":"10760296221119809","DOI":"10.1177\/10760296221119809","article-title":"Application of rotational thromboelastometry in patients with acute promyelocytic leukemia","volume":"28","author":"Sabljic","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"2023112721412733800_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"issue":"7","key":"2023112721412733800_bib29","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023112721412733800_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/mps3040067","article-title":"Fibrin clot formation and lysis in plasma","volume":"3","author":"Larsen","year":"2020","journal-title":"Methods Protoc"},{"key":"2023112721412733800_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2018.04.025","article-title":"Fibrin clot lysis assay: establishment of a reference interval","volume":"167","author":"Neergaard-Petersen","year":"2018","journal-title":"Thromb Res"},{"issue":"2","key":"2023112721412733800_bib32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.thromres.2005.06.006","article-title":"Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers","volume":"118","author":"Brotman","year":"2006","journal-title":"Thromb Res"},{"issue":"5","key":"2023112721412733800_bib33","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1055\/s-0041-1725094","article-title":"Fibrinolysis in venous thromboembolism","volume":"47","author":"Undas","year":"2021","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"2023112721412733800_bib34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.transci.2015.03.008","article-title":"The utility of thromboelastometry in prophylactic platelet transfusion for hematological malignancies","volume":"53","author":"Akay","year":"2015","journal-title":"Transfus Apher Sci"},{"issue":"11","key":"2023112721412733800_bib35","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1097\/CORR.0000000000001832","article-title":"Rotational thromboelastometry findings are associated with symptomatic venous thromboembolic complications after hip fracture surgery","volume":"479","author":"Tsantes","year":"2021","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"2023112721412733800_bib36","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.jamcollsurg.2013.12.039","article-title":"Long-term coagulation changes after resection of thoracoabdominal malignancies","volume":"218","author":"Van Haren","year":"2014","journal-title":"J\u00a0Am Coll Surg"},{"issue":"6","key":"2023112721412733800_bib37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/MBC.0000000000000315","article-title":"Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications","volume":"26","author":"Undas","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"2023112721412733800_bib38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"2023112721412733800_bib39","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/j.ajkd.2006.03.036","article-title":"Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy","volume":"47","author":"Sucker","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2023112721412733800_bib40","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/archinte.1983.00350040068009","article-title":"Increased fibrinolysis and amyloidosis","volume":"143","author":"Liebman","year":"1983","journal-title":"Arch Intern Med"},{"issue":"3","key":"2023112721412733800_bib41","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/0002-9343(85)90321-3","article-title":"Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis","volume":"79","author":"Meyer","year":"1985","journal-title":"Am J Med"},{"issue":"2","key":"2023112721412733800_bib42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/13506120902879269","article-title":"Excessive fibrinolysis in AL-amyloidosis is induced by urokinae-type plasminogen activator from bone marrow plasma cells","volume":"16","author":"Uchiba","year":"2009","journal-title":"Amyloid"},{"issue":"4","key":"2023112721412733800_bib43","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.1989.tb06311.x","article-title":"The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination","volume":"71","author":"Bennett","year":"1989","journal-title":"Br J Haematol"},{"issue":"8","key":"2023112721412733800_bib44","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1538-7836.2004.00787.x","article-title":"Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia","volume":"2","author":"Tallman","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"2023112721412733800_bib45","doi-asserted-by":"crossref","first-page":"666014","DOI":"10.3389\/fonc.2021.666014","article-title":"Case report: ANXA2 associated life-threatening coagulopathy with hyperfibrinolysis in a patient with non-APL acute myeloid leukemia","volume":"11","author":"Ruhnke","year":"2021","journal-title":"Front Oncol"},{"issue":"1-2","key":"2023112721412733800_bib46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.thromres.2004.07.014","article-title":"Annexin II cell surface and mRNA expression in human acute myeloid leukaemia cell lines","volume":"115","author":"Olwill","year":"2005","journal-title":"Thromb Res"},{"issue":"1","key":"2023112721412733800_bib47","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/1097-0142(197007)26:1<142::AID-CNCR2820260118>3.0.CO;2-J","article-title":"Disseminated intravascular coagulation--a complication of chemotherapy in acute myelomonocytic leukemia","volume":"26","author":"Leavey","year":"1970","journal-title":"Cancer"},{"issue":"2","key":"2023112721412733800_bib48","first-page":"146","article-title":"Acute myeloid leukemia with severe coagulation disorder and concomitant central nervous system bleeding - a clinical diagnostic case report","volume":"29","author":"Hatzl","year":"2018","journal-title":"EJIFCC"},{"issue":"4","key":"2023112721412733800_bib49","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/1097-0142(197704)39:4<1618::AID-CNCR2820390436>3.0.CO;2-Q","article-title":"Leukocytic fibrinolysis in myelomonocytic leukemia","volume":"39","author":"Talarico","year":"1977","journal-title":"Cancer"},{"issue":"3","key":"2023112721412733800_bib50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/beha.1999.0034","article-title":"Fibrinolysis and thrombosis","volume":"12","author":"Booth","year":"1999","journal-title":"Baillieres Best Pract Res Clin Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/7056\/2110131\/blooda_adv-2023-011379-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/7056\/2110131\/blooda_adv-2023-011379-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T21:42:19Z","timestamp":1701121339000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/22\/7056\/498125\/Impaired-fibrinolysis-and-increased-clot-strength"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":50,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,11,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011379","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]}}}